NexImmune, Inc. Overview
Pro stress-test →NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM™) technology. The company develops antigen-directed immunotherapies through its AIM nanoparticle platform, directing T cell responses in oncology, autoimmune disease, and infectious disease. Founded in 2011 and headquartered in Maryland, NexImmune targets high-burden hematologic malignancies and immune-mediated conditions with curative potential.
Strategic Profile
Pro stress-test →The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response, combining attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities. Lead programs are focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy.
Competitive Landscape
Pro stress-test →NexImmune competes in the engineered T cell immunotherapy space against established players and emerging biotech competitors. Direct competitors include Iovance Biotherapeutics, Adaptimmune Therapeutics, Inovio Pharmaceuticals, Kite Pharma, and others focused on cell-mediated oncology and autoimmune indications. NexImmune's synthetic dendritic cell platform offers potential differentiation on controllability and reduced toxicity compared to conventional CAR-T and TCR-engineered approaches.
Industry Context
NexImmune, Inc. operates in Engineered T cell immunotherapy.
Key facts
Founded: 2011 · Headquarters: Gaithersburg, Maryland, US · Employees: 51-100 · Revenue: $0 · Market cap: N/A